Bausch Health Companies Inc. (BHC) 2017 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the first quarter 2017 financial results conference call. (Operator Instructions)

    早安。我叫 Melissa,今天將擔任各位的電話會議接線員。此刻,我謹代表公司歡迎各位參加 2017 年第一季財務業績電話會議。(接線員指示)

  • Ms. Elif McDonald, Director of Investor Relations, you may begin your conference.

    投資人關係總監 Elif McDonald 女士,您可以開始會議。

  • Elif McDonald - Director of IR

    Elif McDonald - Director of IR

  • Thank you, Melissa. Good morning, everyone, and welcome to Valeant Pharmaceuticals First Quarter 2017 Financial Results Conference Call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Joe Papa; Chief Financial Officer, Mr. Paul Herendeen; and Executive Vice President Dermatology, Mr. Bill Humphries.

    謝謝你,Melissa。各位早安,歡迎參加 Valeant Pharmaceuticals 2017 年第一季財務業績電話會議。今天與會者包括董事長兼執行長 Joe Papa 先生;財務長 Paul Herendeen 先生;以及皮膚科事業群執行副總裁 Bill Humphries 先生。

  • In addition to the slide webcast, a copy of today's slide presentation and a replay of the conference call will be available on our website under the Investor Relations section.

    除投影片網路直播外,今日投影片簡報的副本以及本次電話會議的重播,將可於本公司網站「投資人關係」專區取得。

  • Before we begin, we would like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information. In addition, this presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website.

    在開始之前,我們提醒各位,今天的簡報包含前瞻性資訊。請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。此外,本簡報包含非 GAAP 財務衡量指標。關於這些衡量指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 調節表可在我們網站上所張貼簡報的附錄中找到。

  • Finally, the financial guidance in this presentation is effective as of today only. It is our policy generally -- to generally not update guidance until the following quarter and only update or affirm guidance through broadly disseminated public disclosure.

    最後,本簡報中的財務指引僅以今日為準。我們的一般政策是——通常不會在下一季之前更新指引,且僅會透過廣泛公開發布的方式更新或重申指引。

  • With that, it is my pleasure to turn the call over to Joe.

    接下來,我很高興把電話交給 Joe。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Thank you, Elif. Good morning, everyone, and thanks for joining us today. Let me start with the topics we'll cover this morning. I'm going to begin with a high-level overview of the progress we've made so far in 2017, particularly since our last earnings call on February 28. I'll then turn the call over to CFO, Paul Herendeen, to review our first quarter financial results. He will also cover the update we have made to our 2017 guidance. I'll then comment on the performance and outlook for our Bausch & Lomb business, our GI business, before turning it over to Bill Humphries to talk about our Dermatology business. He'll wrap up with an update on our new product pipeline before taking your questions.

    謝謝你,Elif。各位早安,感謝今天加入我們。我先從今天早上要討論的主題開始。我將先就我們在 2017 年迄今所取得的進展做一個高層次概述,特別是自 2 月 28 日上次財報電話會議以來的進展。接著我會把電話交給財務長 Paul Herendeen,請他回顧我們第一季的財務結果。他也會說明我們對 2017 年財務指引所做的更新。之後我會評論我們 Bausch & Lomb 業務與腸胃(GI)業務的表現與展望,接著再交給 Bill Humphries 談我們的皮膚科業務。最後他會以新產品研發管線的最新進度作結,然後進入問答。

  • So let's begin. On Slide 4, I want to start with some of the positive developments since our last earnings call, beginning with the strong performance of our 2 largest segments: the B + L/International segment, which represents over half our business, and our Branded Rx segment increased adjusted EBITA by 8% and 12% respectively, year-over-year.

    那我們開始。在第 4 頁投影片,我想先談談自上次財報電話會議以來的一些正面發展,首先是我們兩大事業群的強勁表現:B + L/國際事業群(占我們業務的一半以上)以及品牌處方藥(Branded Rx)事業群,其調整後 EBITA 分別年增 8% 與 12%。

  • Debt reduction continues to be a priority. And I'm pleased to report that to date, we reduced the principal amount of our debt by $3.6 billion since quarter 1 2016. This includes $1.3 billion of debt retired in the first quarter of 2017 with proceeds from the noncore asset sales, including the sale of 3 skincare franchises to L'Oréal, which closed on March 3. And with the successful debt refinancing we completed in March, we extended our maturity profile. Paul Herendeen and Linda LaGorga and our finance team did a great job with the refinancing.

    降低負債仍是優先事項。我很高興報告,截至目前,自 2016 年第一季以來,我們已將債務本金減少 36 億美元。其中包括 2017 年第一季透過出售非核心資產所取得的款項償還的 13 億美元債務,包含將 3 個護膚品牌出售給萊雅(L'Oréal),該交易於 3 月 3 日完成交割。此外,我們在 3 月完成的成功債務再融資,也延長了到期結構。Paul Herendeen、Linda LaGorga 以及我們的財務團隊在再融資方面做得非常出色。

  • In terms of execution, we're raising adjusted EBITDA guidance, which is good news that Paul will cover in more detail later.

    在執行面,我們上調了調整後 EBITDA 指引,這是好消息,Paul 稍後會更詳細說明。

  • In Dermatology, we have stabilized our average selling price or ASPs. Importantly, we saw strong growth in Asia led by China, which was up 11% in volume.

    在皮膚科方面,我們已穩定了平均售價(ASP)。重要的是,我們看到亞洲在中國帶動下的強勁成長,銷量成長 11%。

  • Our Xifaxan Primary Care sales team is gaining new Rx shares since the launch of the sales team in February 2017, and cash flow from operations was great at $954 million for the quarter.

    自 2017 年 2 月成立 Xifaxan 基層醫療(Primary Care)銷售團隊以來,我們的銷售團隊正在取得新的處方(Rx)市占;本季營運活動現金流也非常亮眼,達 9.54 億美元。

  • Moving on to our new product pipeline. We have many positive developments this year, and I'll talk about some of these in more detail later. But briefly, in January, we reported the result of a confirmatory Phase III study of IDP-118, a topical treatment for psoriasis. We are optimistic about these results which demonstrate that the novel formulation IDP-118 could, if approved, be a promising treatment for patients who use a corticosteroid/retinoid combination to treat psoriasis.

    接著談我們的新產品研發管線。今年有許多正面進展,我稍後會更詳細談其中一些。簡要而言,我們在 1 月公布了 IDP-118 的確認性第三期臨床試驗結果,這是一種用於乾癬的外用治療。我們對這些結果感到樂觀;結果顯示,這項新配方 IDP-118 若獲核准,對於使用類固醇/維甲酸類(corticosteroid/retinoid)複方治療乾癬的患者而言,可能是一項具前景的治療選擇。

  • We also received 2 510(k) clearances last month. The first was for the Stellaris Elite vision enhancement system, a next-generation cataract platform that offers many cutting-edge innovations. The second 510(k) clearance was for Vitesse, the first and only hypersonic device for vitreous removal.

    我們上個月也取得 2 項 510(k) 核准。第一項是 Stellaris Elite 視覺增強系統,這是一個新一代白內障平台,提供多項尖端創新。第二項 510(k) 核准是 Vitesse,這是第一個也是唯一用於玻璃體移除的超音速裝置。

  • We also have filed Luminesse, our novel treatment for ocular redness, with the FDA, and we have received a PDUFA date of December 27, 2017. And finally, we've resubmitted Vyzulta with a PDUFA date of August 24, 2017.

    我們也已向 FDA 送件申請 Luminesse(我們用於眼部泛紅的創新療法),並已取得 PDUFA 日期為 2017 年 12 月 27 日。最後,我們已重新提交 Vyzulta,PDUFA 日期為 2017 年 8 月 24 日。

  • Turning now to some of the challenges. Notwithstanding the progress we've made in stabilizing our sales force over the last 3 quarters of 2016, we have been working through some recent challenges. While we recently added more than 250 sales professionals to our GI sales force, those additions were offset by the loss of a number of reps to a new market entrant. We recently took steps to rightsize the Dermatology field force, following a review by our new management.

    接著談一些挑戰。儘管我們在 2016 年最後三個季度已在穩定銷售團隊方面取得進展,但近期仍面臨一些挑戰。雖然我們最近為 GI 銷售團隊新增了 250 多位銷售專業人員,但這些新增人力被部分業務新進競爭者挖角而流失的多名業務代表所抵銷。在新管理團隊審視後,我們近期也採取措施,將皮膚科前線銷售人力調整至適當規模。

  • Moving now to products. While Xifaxan underperformed our expectations in the first quarter, recent TRx market share was up by 200 basis points, and we remain on plan for the year, largely due to the addition of the Primary Care sales force.

    再來談產品。雖然 Xifaxan 第一季表現低於我們的預期,但近期總處方量(TRx)市占上升了 200 個基點;我們仍維持全年計畫進度,主要歸功於新增的基層醫療銷售團隊。

  • Finally, we're in the process of winding down the Commonwealth business, which will further simplify our portfolio and reduce complexity.

    最後,我們正逐步結束 Commonwealth 業務,這將進一步簡化我們的產品組合並降低複雜度。

  • Also, we continue to make progress in resolving the company's legacy legal matters. As you know, we settled the Salix class action litigation last quarter, and separately, we've increased our legal reserve by $76 million this quarter.

    此外,我們也持續在解決公司過往遺留的法律事項方面取得進展。如各位所知,我們在上一季已就 Salix 集體訴訟達成和解;另外,本季我們將法律準備金增加了 7,600 萬美元。

  • In addition, with respect to the SHOWER to SHOWER lawsuits, it is our belief that J&J has obligations to pay for our legal defense and to indemnify Valeant. We have provided Johnson & Johnson with notice that the various lawsuits filed against Valeant relating to SHOWER to SHOWER.

    另外,關於 SHOWER to SHOWER 訴訟,我們認為 J&J 有義務支付我們的法律辯護費用並對 Valeant 進行賠償(indemnify)。我們已向 Johnson & Johnson 發出通知,告知針對 Valeant 提起、與 SHOWER to SHOWER 相關的各項訴訟。

  • On that note, I'll turn the call over to Paul to go through our first quarter financial results in details.

    說到這裡,我把電話交給 Paul,請他詳細說明我們第一季的財務結果。

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • Thank you, Joe. On a reported basis, revenue was down 11% compared with Q1 of '16. Unfavorable movements in FX rates accounted for roughly 200 basis points of the decline. As expected, the lion's share of the decline came from our Diversified segment, where revenue was down $206 million.

    謝謝你,Joe。以申報口徑(reported basis)計算,營收較 2016 年第一季下滑 11%。匯率(FX)不利變動約占下滑幅度的 200 個基點。如預期,降幅的主要來源來自我們的多元化(Diversified)事業群,該事業群營收減少 2.06 億美元。

  • From a revenue perspective, B + L/International posted a solid quarter. It was flat on a reported basis but up 4% on a constant currency basis.

    從營收角度來看,B + L/國際業務本季表現穩健。按申報口徑計算持平,但按固定匯率口徑計算成長4%。

  • Branded Rx was down 9% or $61 million versus the year-ago quarter. Our adjusted gross margin was down roughly 310 basis points compared with Q1 of '16, and most of that decline in overall gross margin was due to mix, as the revenue declines were in our higher gross margin business units.

    品牌處方藥(Branded Rx)較去年同期季度下滑9%,或減少6,100萬美元。我們的調整後毛利率較2016年第一季約下降310個基點,而整體毛利率下滑的大部分原因來自產品組合,因為營收下滑主要發生在我們毛利率較高的業務單元。

  • In operating expenses, selling, advertising and promotional expenses were down $108 million compared with last year, almost entirely due to lesser A&P spending. Adjusted G&A costs were up $22 million as we incurred costs in Q1 of 2017, but outside legal services in connection with ongoing actions and for consulting services in connection with our continuing efforts to streamline our global operations.

    在營業費用方面,銷售、廣告與促銷費用較去年減少1.08億美元,幾乎完全是因A&P支出較少所致。調整後的一般與行政(G&A)成本增加2,200萬美元,因我們在2017年第一季發生了相關成本,主要為與持續進行的訴訟行動相關的外部法律服務費,以及與我們持續精簡全球營運之努力相關的顧問服務費。

  • Our investment in R&D was down $7 million from the prior year quarter. However, this was due to the timing of costs on our various R&D projects and does not portend a reduction in our R&D activity. We continue to expect our investment in R&D for the full year of 2017 to be an increase over 2016.

    我們在研發(R&D)上的投資較去年同期季度減少700萬美元。然而,這是由於我們各項研發專案成本發生時點的差異,並不意味著我們的研發活動將減少。我們仍預期2017年全年研發投資將較2016年增加。

  • Our adjusted EBITDA declined $147 million or 15% compared with Q1 of '16. If you wanted to pick 1 factor that most contributed to the decline in adjusted EBITDA, it would be the impact of LOEs on our Diversified segment. Together, the neuro and Generics units saw a revenue decline by $214 million, and those are high-margin revenues.

    我們的調整後EBITDA較2016年第一季下降1.47億美元,或15%。若要挑出一個對調整後EBITDA下滑貢獻最大的因素,那就是專利到期(LOE)對我們多元化(Diversified)部門的影響。神經科(Neuro)與學名藥(Generics)兩個單元合計營收下降2.14億美元,而這些屬於高毛利營收。

  • Let me cover some of the major themes in our 3 segments, starting with the B + L/International segment. On a reported basis, the segment was flat compared with the first quarter of '16. However, as I said, on a constant currency basis, it grew 4% with roughly 140 basis points of that growth coming from realized net price increases across the segment. The international portion of the segment delivered 3% reported revenue growth but 15% growth on a constant currency basis. A portion of that increase was due to the steps we took in early 2016 to destock the pipeline inventories of several of our Eastern European units. Regardless, our international units delivered a strong first quarter.

    我來說明我們三大部門的一些主要主題,先從B + L/國際部門開始。按申報口徑,該部門較2016年第一季持平。不過如我所述,按固定匯率口徑成長4%,其中約140個基點的成長來自整個部門已實現的淨價格上調。該部門中的國際部分按申報口徑營收成長3%,但按固定匯率口徑成長15%。其中一部分增幅來自我們在2016年初採取的措施,對我們若干東歐單元的通路庫存進行去庫存(destock)。無論如何,我們的國際單元在第一季交出強勁表現。

  • Global Ophtho Rx revenue was up 1% on a reported basis and 3% on a constant currency basis, with our international units more than offsetting a slight decline in the U.S. The Global Consumer business showed modest revenue growth while Global Surgical and Vision Care declined.

    全球眼科處方藥(Global Ophtho Rx)營收按申報口徑成長1%,按固定匯率口徑成長3%,其中國際單元的表現足以抵消美國市場的小幅下滑。全球消費者(Global Consumer)業務營收小幅成長,而全球外科(Global Surgical)與視力保健(Vision Care)則下滑。

  • Yes, we're in the process of reorganizing and reconfiguring the B&L and International businesses to ensure efficiency in our operations and to provide the support for future growth. In Q1 of 2017, you can see a bit of improved operating expense efficiency within SG&A, as SG&A declined compared with 2016. We believe the improved revenue growth will follow. Adjusted EBITA for the segment on a constant currency basis grew faster than revenue, up 8%, a solid performance.

    是的,我們正在重整並重新配置B&L與國際業務,以確保營運效率並為未來成長提供支援。在2017年第一季,你可以看到SG&A中的營業費用效率有所改善,因為SG&A較2016年下降。我們相信營收成長的改善將隨之而來。該部門的調整後EBITA按固定匯率口徑成長速度快於營收,成長8%,表現穩健。

  • On to Slide 7 and the Branded Rx segment, where revenue was down 9% with both our GI and Derm businesses off 11% compared with Q1 of '16. Before I start, the change in wholesale pipeline inventories was not particularly notable in the quarter. We've included a schedule in the appendix on Slide 32 that you can use to gain additional perspective into the sales growth or declines in our Rx units, including Derm, GI, Ophtho, Neuro and Generics.

    接著看投影片7與品牌處方藥(Branded Rx)部門,營收下滑9%,其中腸胃科(GI)與皮膚科(Derm)業務相較2016年第一季均下滑11%。在我開始之前,本季批發通路庫存的變動並不特別顯著。我們在附錄投影片32中提供了一份明細表,供你用來更深入了解我們處方藥各單元(包括Derm、GI、Ophtho、Neuro與Generics)的銷售成長或下滑情況。

  • So Derm. Yes, the transition of the Derm business away from the specialty pharmacy-driven models continues. As a result, Derm revenues are down on lesser volumes, but that's not the entire story. In the quarter, we enjoyed higher ASPs and higher gross profit margins, and those revenues and profits were driven by leaner, more focused sales force. 2017 is a transitional year for Derm. But importantly, we expect the Derm unit to contribute a similar amount of profit in 2017 as in 2016. Also of note in Q1 '17 versus '16, we realized 530 basis points of increased net pricing across the Derm unit, with roughly 1/3 of that increase coming from improved management of gross-to-net items.

    先談Derm。是的,Derm業務持續從以專科藥局驅動的模式轉型。因此,Derm營收因銷量較低而下滑,但這並非全部原因。本季我們的平均銷售價格(ASP)更高、毛利率也更高,而這些營收與利潤是由更精簡、更聚焦的銷售團隊所帶動。2017年是Derm的轉型年。但重要的是,我們預期Derm單元在2017年的利潤貢獻將與2016年相近。另外值得注意的是,2017年第一季相較2016年第一季,我們在Derm單元整體實現淨定價提升530個基點,其中約1/3來自對毛到淨(gross-to-net)項目的管理改善。

  • On to GI. GI is all about Xifaxan. The story here is that we lost some momentum over the fourth quarter of last year and into the first quarter of '17. That was due, in part, to the rumored sale of Salix last year and then early this year when we lost a number of sales reps to a new competitor all at one time.

    接著談GI。GI的核心就是Xifaxan。這裡的情況是,我們在去年第四季到2017年第一季之間動能有所減弱。部分原因是去年市場傳聞Salix將被出售,以及今年年初我們在同一時間點流失了多名銷售代表到一家新競爭對手。

  • Over the last 9 weeks, however, our sales forces have regained their footing, and we have seen Xifaxan 550 gain roughly 200 basis points of TRx share in its segment. In the quarter, we realized about 310 basis points of increased net selling price in the Salix unit.

    不過在過去9週,我們的銷售團隊已重新站穩腳步,我們看到Xifaxan 550在其細分市場中的TRx市占率提升約200個基點。本季我們在Salix單元實現約310個基點的淨售價提升。

  • Below the sales line in Branded Rx, our gross margin was essentially flat. Selling, advertising and promotional expenses were down $87 million. In Q1 of 2016, we spent heavily on direct-to-consumer advertising in support of several brands, particularly Jublia and Xifaxan. We're not repeating those activities in 2017.

    在品牌處方藥(Branded Rx)中,銷售額以下的毛利率基本持平。銷售、廣告與促銷費用減少8,700萬美元。在2016年第一季,我們為支持多個品牌投入大量面向消費者的直接廣告(DTC),尤其是Jublia與Xifaxan。我們在2017年不會重複這些活動。

  • Within SA&P, our selling expenses were essentially flat compared with the prior year quarter, a fact that highlights our efforts to allocate capital responsibly within our businesses. Selling expense in Q1 of '17 includes the cost of the new Primary Care sales force to promote Xifaxan and other products in the Primary Care setting and the expansion of our patient access and sales operations teams. But a good portion of those increased costs were offset by the rightsizing of our Derm sales force. G&A costs in the segment were up $9 million mainly due to increased legal expenses. Segment EBITA was up 12%, with the year-over-year decrease in A&P spending in the quarter a major driver of that growth.

    在SA&P之中,我們的銷售費用相較去年同期季度基本持平,這一點凸顯我們在各項業務中負責任地配置資本的努力。2017年第一季的銷售費用包含新成立的基層醫療(Primary Care)銷售團隊成本,用於在基層醫療場域推廣Xifaxan及其他產品,以及擴充我們的病患可近性與銷售營運團隊。但其中相當一部分增加的成本,已由我們對Derm銷售團隊的規模調整所抵銷。該部門的G&A成本增加900萬美元,主要因法律費用上升。部門EBITA成長12%,其中本季A&P支出年減是推動成長的主要因素。

  • On to Slide 8, the Diversified segment. The diversified segment is comprised -- mainly comprised of product assets and businesses that are noncore. We manage these assets for cash generation. And while you may not see it because of the overwhelming impact of LOEs on this portfolio, our diversified team has done a very good job of actively managing these assets. The story in Q1 is the impact of the LOEs in the Neuro and Generics units. In conjunction with our guidance back in February, we provided a look at our expectations for the impact of the LOE products on 2017. We've updated that exhibit on Slide 23 in the appendix.

    接著看投影片8,多元化(Diversified)部門。多元化部門由產品資產與非核心業務所構成——主要由非核心項目構成。我們管理這些資產以創造現金流。雖然你可能因專利到期(LOE)對該投資組合的巨大影響而不易看出,但我們的多元化團隊在積極管理這些資產方面做得非常好。第一季的重點是LOE對神經科(Neuro)與學名藥(Generics)單元的影響。配合我們在2月發布的財測指引,我們提供了對2017年LOE產品影響的預期概覽。我們已在附錄的投影片23更新了該圖表。

  • LOE products drove the decline in the Diversified segment in Q1. Revenues were down 37%, and adjusted EBITDA down 43%. There's a lot of material in our slides, so that's all I'll cover for now with respect to our operating results, but I do want to take a few minutes to talk about our liquidity and the series of debt transactions that we completed during the quarter.

    LOE 產品帶動多元化事業部在第一季下滑。營收下降 37%,調整後 EBITDA 下降 43%。我們的投影片裡有很多內容,所以就營運結果而言我先講到這裡,但我確實想花幾分鐘談談我們的流動性,以及我們在本季完成的一系列債務交易。

  • Just a few things to point out on our balance sheet summary on Slide 9. We ended the quarter with $1.2 billion of cash on hand and reduced our debt by almost $1.3 billion in the quarter. Compared with March 31, 2016, our quarter-end debt balance was down $3.4 billion, and you did see that we paid down an additional $220 million of debt just last week. We believe strongly that we have clear pathways to get our capital structure in order by: one, reducing our leverage throughout the sales; two, through cash generation; and three, the best way, through growth our operating earnings. That said, as we entered 2017, we were facing a wall of maturities in 2018, '19 and '20, and we're operating the financial covenants that left us with only a modest margin of error and restricted our ability to take actions to improve our prospects.

    先就第 9 頁投影片的資產負債表摘要指出幾點。本季結束時,我們手上現金為 12 億美元,且本季將債務減少了將近 13 億美元。與 2016 年 3 月 31 日相比,我們季末債務餘額減少了 34 億美元,而且你們也看到我們就在上週又額外償還了 2.2 億美元的債務。我們堅信,我們有清晰的途徑讓資本結構回到正軌:第一,透過出售資產來降低槓桿;第二,透過現金創造;第三,也是最好的方式,透過提升營運獲利來成長。話雖如此,當我們進入 2017 年時,面臨 2018、2019 與 2020 年到期的債務高牆,同時我們受制於財務契約條款,容錯空間不大,並限制了我們採取行動以改善前景的能力。

  • So what do we do about it? Turn to Slide 10. Slide 10 shows our upcoming debt maturities after using of the proceeds from the sale of the skincare assets to reduce debt and then the completion of our debt transactions back in March. We think that completing the debt transaction was a significant event that, in my opinion, was underappreciated by the markets. By refinancing the debt, we now have a very manageable debt pay down schedule for the next several years. We shifted about -- to about 75% fixed versus floating rate debt. And finally, we substantially improved our covenant position.

    那我們怎麼做?請看第 10 頁投影片。第 10 頁顯示在我們運用出售護膚資產的所得款項來減債,並於 3 月完成債務交易之後,未來的債務到期情形。我們認為完成這項債務交易是一個重大事件,就我看來,市場對此的重視程度不足。透過再融資,我們未來幾年的債務償還時程已變得非常可控。我們將債務結構調整為約 75% 固定利率、相對於浮動利率。最後,我們也大幅改善了契約條款(covenant)狀況。

  • So what do we get? Yes, we gain the time and the flexibility to continue the work that started last year to put the company on a path to sustainable, profitable growth. We provided ourselves with a runway to continue our efforts to divest noncore assets without the time pressures that could lead to suboptimal transactions. We got peace of mind.

    那我們得到什麼?是的,我們獲得時間與彈性,得以持續去年開始的工作,讓公司走上可持續且具獲利性的成長道路。我們也為自己爭取了跑道,得以在沒有時間壓力、避免導致不理想交易的情況下,持續剝離非核心資產。我們獲得了安心。

  • Now I've heard chatter in the markets that Valeant doesn't have the ability to repay all of its debt. Let me respond. We can meet all of our financial obligations through a combination of cash generation for our business, asset sales and, importantly, refinancings. There's a permanent role for debt in our capital structure. The goal is not to repay all of our debt and operate debt-free. The goal is to maintain a credit profile that will enable us to access the capital markets when necessary to fund our future capital requirements, including to refinance maturing debt. I've been a debt guy for the vast majority of my career. I've been the CFO of several highly leveraged companies. With these debt transactions in our rearview mirror, I'm comfortable with our position here.

    我也聽到市場上有些議論,說 Valeant 沒有能力償還全部債務。我來回應一下。我們可以透過營運所產生的現金、資產出售,以及重要的再融資組合,來履行我們所有的財務義務。在我們的資本結構中,債務有其長期且固定的角色。目標不是把所有債務都還清、以零負債營運。目標是維持一個信用概況,使我們在必要時能進入資本市場,以支應未來資金需求,包括為到期債務進行再融資。我職涯大部分時間都在做債務相關工作。我也曾擔任數家高槓桿公司的財務長。在這些債務交易已成過去之後,我對我們目前的處境感到放心。

  • To be clear, we still have a lot of work to do, and I promise each and every one of you that the team here will focus every day to chart and execute the steps needed to get our capital structure right side up. I say all the time, if we take care of our debt, and we will, our equity will take care of itself.

    坦白說,我們仍有很多工作要做,我也向在座每一位承諾,團隊每天都會專注於規劃並執行讓資本結構回到正軌所需的步驟。我常說,只要我們把債務照顧好——而我們一定會——我們的股權自然會水到渠成。

  • Let's turn to the cash flow in the quarter. On Slide 11, you see that we generated $954 million of cash from ops in the quarter. Looking backward over the last 5 quarters, a more normal level of cash generation from ops might be in the range of $500 million to $550 million. So cash flow from ops in Q1 was likely higher than you might have expected. Roughly $200 million of that was due to the timing of cash we received under our agreement with Walgreens. We also generated a fair amount of cash from the reduction of working capital due to the sequential decline of revenue from Q4.

    接著看本季的現金流。在第 11 頁投影片,你會看到本季我們由營運產生 9.54 億美元現金。回顧過去 5 個季度,較正常的營運現金創造水準可能落在 5 億至 5.5 億美元之間。因此第一季的營運現金流可能高於你原先的預期。其中約 2 億美元來自我們與 Walgreens 協議下收到現金的時間點因素。我們也因第四季營收連續下滑,帶動營運資金下降,而產生了相當可觀的現金。

  • It's worth pointing out that compared with the end of Q1 of last year, we made substantial progress in the management of our working capital. A lot of work remains to be done, but we're focused on unlocking cash from our balance sheet for sure.

    值得指出的是,與去年第一季末相比,我們在營運資金管理方面已取得顯著進展。仍有許多工作要做,但我們確實專注於從資產負債表中釋放現金。

  • Away from operations, we realized $1.3 billion upon the closing of the sale of the skincare assets to L'Oréal, and we used $1.1 billion of those proceeds to prepay debt. In the aggregate, we did reduce debt in the quarter by $1.3 billion.

    在營運之外,我們在將護膚資產出售給萊雅(L'Oréal)完成交割時實現了 13 億美元收入,並將其中 11 億美元用於提前償還債務。整體而言,我們本季確實將債務減少了 13 億美元。

  • Onto the guidance on Slides 12 and 13. In a nutshell, we're maintaining our guidance range for revenue and raising our guidance range for adjusted EBITDA by $50 million despite the impact of the skincare asset sales. When we originally gave guidance back in February, it did not reflect anticipated asset sales. The change from our prior guidance comes mainly from the impact of the divested skincare assets, which, as we previously disclosed, decreased our 2017 revenue expectations by $160 million and our adjusted EBITDA expectations by $70 million and our revised estimates of the impact of the LOE products on 2017, where we increased our revenue expectations by $110 million, and adjusted EBITDA by approximately the same amount. See Slide 13 for the bridge.

    接著看第 12 與第 13 頁投影片的財測指引。簡而言之,儘管護膚資產出售帶來影響,我們仍維持營收指引區間不變,並將調整後 EBITDA 指引區間上調 5,000 萬美元。我們在 2 月最初提供指引時,並未反映預期的資產出售。相較先前指引的變動,主要來自已剝離的護膚資產影響;如我們先前揭露,該交易使我們 2017 年營收預期減少 1.6 億美元、調整後 EBITDA 預期減少 7,000 萬美元;以及我們對 2017 年 LOE 產品影響的修正估計,我們將營收預期上調 1.1 億美元,調整後 EBITDA 也大致上調相同幅度。請參見第 13 頁的銜接表。

  • I want to point out that our guidance does not assume closing of the sale of Dendreon to Sanpower. We expect to close that transaction around midyear, and we'll adjust our guidance when the timing impact on 2017 results are more clear.

    我想指出,我們的指引並未假設 Dendreon 出售給 Sanpower 的交易完成交割。我們預期該交易將在年中左右完成,待其對 2017 年業績的時間點影響更明確後,我們會調整指引。

  • One last quick note for modelers. We've included additional financial information that you may find helpful in the appendix at Slide 24.

    給建立模型的各位最後一個簡短提醒。我們在第 24 頁投影片的附錄中加入了你們可能會覺得有用的額外財務資訊。

  • With that, let me turn it back to Joe.

    接下來,我把時間交回給 Joe。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Thank you, Paul. As I mentioned briefly in my opening remarks, we have made a number of noncore divestitures that have enabled us to simplify our operating model and reduce our debt.

    謝謝你,Paul。如我在開場致詞中簡要提到的,我們已完成多項非核心資產剝離,使我們得以簡化營運模式並降低債務。

  • The chart on Slide 14 shows the progress we have made in closing these transactions. As you can see, we have now closed 8 of the 10 asset sales we announced, and we continue to expect Dendreon to close midyear. Upon completion of the divestiture in this chart, we will generated total potential proceeds of $2.7 billion. We reiterate our expectation to pay down $5 billion of debt from divestiture proceeds and free cash flow by February 2018, and we are well on our way to delivering on this goal.

    第 14 頁投影片的圖表顯示我們在完成這些交易方面取得的進展。如你所見,我們已完成所宣布 10 項資產出售中的 8 項,並仍預期 Dendreon 將於年中完成交割。在完成此圖表所列的剝離後,我們將可取得合計最高 27 億美元的潛在所得款項。我們重申預期在 2018 年 2 月前,透過剝離所得與自由現金流償還 50 億美元債務,而我們正穩步朝達成此目標前進。

  • First quarter revenues for Bausch + Lomb/International segment on Slide 15 were $1.15 billion, and adjusted EBITA growth was up 8% in constant currency. Internationally, we have a solid market leadership position in contact lenses. To call out a few highlights, we have a 30% share of the contact lens market in China and a 60% market share in India, 2 fast growing markets. Asia is a significant growth driver for the business, particularly in China, where Bausch & Lomb is celebrating its 30th anniversary. And that milestone is generating opportunities to create excitement about the brand.

    第 15 頁投影片顯示,Bausch + Lomb/國際事業部第一季營收為 11.5 億美元,按固定匯率計算的調整後 EBITA 成長 8%。在國際市場,我們在隱形眼鏡領域具備穩固的市場領導地位。舉幾個重點,我們在中國隱形眼鏡市場的市占率為 30%,在印度的市占率為 60%,這兩個都是快速成長的市場。亞洲是該業務的重要成長動能,尤其是在中國,Bausch & Lomb 正在慶祝其 30 週年。而這個里程碑正帶來機會,為品牌創造更多話題與熱度。

  • Our consumer products business also remains strong. To call a few highlights, PreserVision and Ocuvite are now the #1 ocular vitamin brands globally; Biotrue is the #1 multipurpose solution brand with the highest loyalty metrics; and PreserVision AREDS 2 formula, the 120 count, is the #1 selling vitamin item in the United States.

    我們的消費者產品業務也依然強勁。舉幾個亮點來說,PreserVision 與 Ocuvite 現已成為全球排名第 1 的眼部維生素品牌;Biotrue 是忠誠度指標最高的排名第 1 多功能護理液品牌;而 PreserVision AREDS 2 配方(120 粒裝)則是美國銷售排名第 1 的維生素單品。

  • Finally, we are advancing new products through our pipeline. In addition to receiving 510(k) clearances in April for Stellaris and Elite and Vitesse, we have a PDUFA date for Vyzulta in August 2017 and Luminesse in December 2017.

    最後,我們正透過研發管線推進新產品。除了 Stellaris、Elite 與 Vitesse 已於 4 月取得 510(k) 核准外,Vyzulta 的 PDUFA 日期為 2017 年 8 月,Luminesse 則為 2017 年 12 月。

  • Moving on now to our GI business on Slide 16. We are seeing some promising script trends as we exit first quarter that we expect to continue in the back half of the year. Apriso TRx growth was up 9% year-over-year. Relistor was up 12%. And although Xifaxan new Rx were reasonably flat year-over-year, a new Rx as a leading indicator grew approximately 10% from January to March.

    接下來看第 16 張投影片的腸胃(GI)業務。在第一季結束之際,我們看到一些令人鼓舞的處方趨勢,預期將在下半年延續。Apriso 的 TRx 年增 9%。Relistor 年增 12%。雖然 Xifaxan 的新處方(new Rx)年比大致持平,但作為領先指標的新處方自 1 月至 3 月約成長 10%。

  • In addition, Xifaxan Primary Care target market share has increased by 440 basis points since February, and we continue to expect to ramp in the second half due to our sales force expansion.

    此外,自 2 月以來,Xifaxan 在基層醫療(Primary Care)目標市場的市占率已提升 440 個基點;由於我們擴編銷售團隊,我們仍預期下半年將加速成長。

  • Finally, the draft for [Xifaxan] guidance that the FDA issued in March raises important questions about generic formulations and may impact the approval of Generics. We believe the new generic requirements are a step in the right direction to confirm product effectiveness. We continue to be confident in our legal position in the existing Xifaxan ANDA litigation.

    最後,FDA 於 3 月發布的 [Xifaxan] 指引草案,對學名藥配方提出重要疑問,並可能影響學名藥的核准。我們認為新的學名藥要求是朝確認產品有效性邁出的正確一步。對於現行 Xifaxan ANDA 訴訟,我們仍對自身的法律立場充滿信心。

  • On Relistor, we are seeing new Rx writer growth of 26% since launch in September 2016, and we now have more than 80% of covered lives. The PCP sales force is benefiting from Relistor also, with TRx market share up 150 basis points from January to March.

    在 Relistor 方面,自 2016 年 9 月上市以來,我們看到新處方開立醫師數成長 26%,目前覆蓋人群(covered lives)已超過 80%。基層醫療(PCP)銷售團隊也受惠於 Relistor,TRx 市占率自 1 月至 3 月提升 150 個基點。

  • In Dermatology, we have recruited an experienced team, and we are preparing to launch new products on Slide #17. Bill Humphries, who's here with us today, joined Valeant this past January to lead our Dermatology business. Before joining Valeant, Bill was the CEO of Merz North America from 2012 to 2016. Before that, he was President of Stiefel, a global leader in Dermatology and skin health. He also had multiple senior roles at Allergan, including Vice President of U.S. Skincare business. And we're going to ask Bill to take us through the next slide and share his perspective on the outlook of Dermatology business. Bill?

    在皮膚科方面,我們已招募一支經驗豐富的團隊,並正準備在第 17 張投影片推出新產品。今天也在現場的 Bill Humphries 於今年 1 月加入 Valeant,領導我們的皮膚科業務。加入 Valeant 之前,Bill 於 2012 至 2016 年擔任 Merz 北美區執行長。在此之前,他曾擔任 Stiefel 總裁;Stiefel 是皮膚科與皮膚健康領域的全球領導者。他也曾在 Allergan 擔任多項高階職務,包括美國護膚業務副總裁。接下來我們請 Bill 帶我們看下一張投影片,並分享他對皮膚科業務前景的看法。Bill?

  • William D. Humphries - EVP and Company Group Chairman of Dermatology

    William D. Humphries - EVP and Company Group Chairman of Dermatology

  • Thank you, Joe. As Joe mentioned, I joined Valeant at the beginning of the year, and I'm very excited to be here. I'd like to start by running through some of the first quarter highlights for the Dermatology business and sharing my perspective on our goals and priorities for the remainder of the year.

    謝謝你,Joe。如 Joe 所提,我在年初加入 Valeant,我非常興奮能在這裡。我想先回顧皮膚科業務第一季的一些重點,並分享我對今年剩餘期間目標與優先事項的看法。

  • First and foremost, we've taken a series of actions to further stabilize the business. This includes recruiting a new and experienced team. Valeant has a long track record in the Dermatology space, and we continue to attract and retain excellent talent.

    首先也是最重要的,我們已採取一系列行動,進一步穩定業務。其中包括招募一支新的、經驗豐富的團隊。Valeant 在皮膚科領域有長期的深厚基礎,我們也持續吸引並留任優秀人才。

  • In terms of our sales force, we rightsized the number of representatives in the field and organized them around roughly 150 territories. Our team is in the midst of a 9-city management tour to rebuild relationships with the doctors and other healthcare providers who prescribe and recommend our products. This is a useful exercise for our team that is yielding important insights into our business.

    就銷售團隊而言,我們已將外勤代表人數調整至適當規模,並以約 150 個區域進行編組。我們的團隊正進行一項涵蓋 9 個城市的管理巡迴,以重建與開立處方及推薦我們產品的醫師與其他醫療照護提供者之關係。這對團隊而言是很有價值的工作,也為我們的業務帶來重要洞見。

  • We've coupled these efforts with a very strong presence at first quarter dermatology and podiatry conferences to talk about the changes we are making and to rebuild relationships with those stakeholders. As we undertake these actions, we remain focused on profitability. ASPs have stabilized, and we have adjusted copay caps.

    我們也在第一季的皮膚科與足病醫學(podiatry)研討會上投入非常強的參與度,說明我們正在進行的變革,並重建與相關利害關係人的關係。在推動這些行動的同時,我們仍專注於獲利能力。平均售價(ASP)已趨於穩定,我們也調整了自付額(copay)上限。

  • I'm most excited about our efforts to reinvigorate our portfolio and prepare for a new growth driver. Our team is working hard to prepare for the upcoming launch of SILIQ, which was approved in February and is expected to launch midyear. When it's launched, SILIQ will be the most competitively priced injectable biologic for the treatment of moderate-to-severe plaque psoriasis. As an IL-17 blocker, it will be a differentiated product, and we are very excited about its efficacy profile.

    我最感到振奮的是,我們正努力讓產品組合重獲活力,並為新的成長動能做準備。團隊正全力為 SILIQ 的即將上市做準備;該產品已於 2 月獲核准,預計於年中上市。上市後,SILIQ 將成為治療中度至重度斑塊型乾癬、價格最具競爭力的可注射生物製劑。作為 IL-17 阻斷劑,它將是一項具差異化的產品,我們對其療效表現非常期待。

  • Finally, as Joe mentioned in his opening remarks, we also have IDP-118 in the pipeline, which we believe has the potential to be a very promising topical product for the treatment of psoriasis.

    最後,如 Joe 在開場致詞中提到,我們的研發管線中還有 IDP-118;我們相信它有潛力成為治療乾癬非常有前景的外用產品。

  • So with those comments, I'll turn it back over to you, Joe.

    以上是我的補充,接下來我把時間交回給你,Joe。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Thank you, Bill. Moving to Slide 19, new product launches. This is an area where I am particularly excited about, because these new product launches are the drivers of our future growth. Year-to-date, we have launched 20 new products. And this year, we expect to launch more than 50 new products globally, which we anticipate to generate approximately $100 million of sales.

    謝謝你,Bill。接著看第 19 張投影片:新產品上市。這是我特別感到興奮的領域,因為這些新產品上市將驅動我們未來的成長。截至目前,我們已推出 20 項新產品。而今年我們預期在全球推出超過 50 項新產品,預估可帶來約 1 億美元的銷售額。

  • Moving on to Slide 20. As you can see from this list, our R&D organization is robust and productive, and we have the strength in our late-stage pipeline. A special thanks to -- goes out to all of the 1,000-plus Valeant employees who are working on our R&D organization globally for their continued progress. These innovations will be the foundation of our future growth, and we look forward to bringing new products to the market that will improve peoples' lives.

    接著看第 20 張投影片。從這份清單可見,我們的研發(R&D)組織健全且高產出,並且在後期研發管線具備實力。特別感謝全球研發組織中 1,000 多位 Valeant 員工持續推進相關進展。這些創新將成為我們未來成長的基礎,我們也期待將能改善人們生活的新產品帶入市場。

  • To conclude, on Slide 21, our first quarter results confirm these steps we have taken to stabilize the business and deliver on our commitments are resulting in steady, measurable progress that will lead us through the turnaround phase in the 2017 to 2018 time frame.

    總結來說,在第 21 張投影片,我們第一季的結果證實:我們為穩定業務並履行承諾所採取的這些步驟,正帶來穩定且可衡量的進展,並將在 2017 至 2018 年期間引領我們走過轉型復甦階段。

  • As a recap, we continue to strengthen our balance sheet. We are encouraged by the strong performance of our B&L/International and Branded Rx segments, which grew adjusted EBITA by 8% and 12%, respectively. We continue to manage our Diversified Products business for cash generation, and our business produced strong cash flow from operations of $954 million this quarter.

    回顧一下,我們持續強化資產負債表。我們對 B&L/國際與品牌處方藥(Branded Rx)部門的強勁表現感到鼓舞,兩者調整後 EBITA 分別成長 8% 與 12%。我們持續以現金創造為目標管理多元化產品(Diversified Products)業務,而本季營運活動所產生的強勁現金流達 9.54 億美元。

  • We remain focused on specialty-driven markets with above-average growth rates, like Dermatology and GI. We are encouraged that our Primary Care sales team performance and the increased market share gains they've seen, just -- and how they exited the quarter. Our pipeline continues to produce innovative new products as we prepare to launch more than 50 new products globally this year. And finally, we've raised our adjusted EBITDA guidance.

    我們仍聚焦於成長率高於平均的專科驅動市場,例如皮膚科與腸胃(GI)。我們也對基層醫療(Primary Care)銷售團隊的表現及其市占率提升感到鼓舞,尤其是他們在季度末的表現。隨著我們準備今年在全球推出超過 50 項新產品,我們的研發管線持續產出具創新性的新品。最後,我們已上調調整後 EBITDA 指引。

  • With that, operator, let's open up the line for questions.

    以上,接線員,請開放電話線供提問。

  • Operator

    Operator

  • (Operator Instructions) Your first question comes from the line of Gregg Gilbert from Deutsche Bank.

    (接線員指示)您的第一個問題來自德意志銀行(Deutsche Bank)的 Gregg Gilbert。

  • Gregory B. Gilbert - MD and Senior Analyst

    Gregory B. Gilbert - MD and Senior Analyst

  • I'll ask 1, few-part question. First on Xifaxan, I think you said inventory in the channel didn't change much for the business. So there must have been a lot going on in gross-to-net. So perhaps you can speak to that as well as the latest your dispute with Alfa Wassermann? And the third part of my question, maybe for Bill, since you're on the call. Maybe you can frame for us whether you're layering the new launch story in Derm on top of an eroding base, stable base or growing base and help us understand the prospects for the non-new launch part of the story.

    我會問一個由幾個部分組成的問題。首先關於 Xifaxan,我想您提到通路端的庫存對業務而言變化不大。所以毛額到淨額(gross-to-net)之間一定發生了很多變化。因此也許您可以談談這點,以及您與 Alfa Wassermann 的爭議最新進展?第三部分的問題,可能給 Bill,既然你也在電話上。也許你可以幫我們界定一下:你們在皮膚科(Derm)把新的上市故事疊加在一個正在流失的基礎、穩定的基礎,還是成長的基礎之上,並幫助我們理解「非新上市」那部分故事的前景。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • All right, I'll start with the first 2-part, and then I'll turn it over to Bill on the Derm question. Let me start with Xifaxan question. Yes, they -- their -- the -- as Paul pointed out in the appendix on I think it's Slide #32, the GI business, it came down slightly in the first quarter versus -- but basically, it's very -- it's flat, is the first comment. On the question of where we are with gross-to-net, the gross-to-nets for Xifaxan are essentially flat year-over-year. In fact, for the entire company year-over-year. We, during the first quarter of 2016 and then through now, really took a look at what we were doing, adjusted the incremental rebates that we needed to get to. And since that time, I think we've tried to stay on balance relatively flat. I mean, there is a slight change as a total company. I think our gross-to-nets went up very slightly, but, for the most part, they've been relatively stable. The big question for us on Xifaxan was the Rxs during the quarter. As I said, it was relatively flat versus a year ago, but what we've really tried to focus on right now is the growth as we've seen it and how the growth is projecting with the TRx and newer Rx share, predominantly because of some of the capabilities we've added in our Primary Care team. As I said, there's a number of real positive indicators there for the future and where we're going.

    好的,我先回答前兩個部分,然後把皮膚科的問題交給 Bill。我先從 Xifaxan 的問題開始。是的——如 Paul 在附錄中指出的,我想是在第 32 張投影片,GI(腸胃)業務在第一季相較於——略有下降,但基本上非常——第一個重點是持平。至於我們在毛額到淨額(gross-to-net)方面的狀況,Xifaxan 的 gross-to-net 基本上與去年同期持平。事實上,整個公司與去年同期相比也是如此。我們在 2016 年第一季以及直到現在,確實重新檢視了我們在做的事情,並調整了我們需要達到的增量回扣(incremental rebates)。自那之後,我想我們一直努力維持相對持平的平衡狀態。我的意思是,從全公司角度看確實有些微變化。我認為我們的 gross-to-net 略微上升,但大部分時間都相對穩定。對我們而言,Xifaxan 的最大問題是本季的處方量(Rxs)。如我所說,與去年同期相比相對持平,但我們目前真正聚焦的是我們所看到的成長,以及 TRx 與新處方(newer Rx)市占的成長投射,主要是因為我們在基層醫療(Primary Care)團隊新增了一些能力。如我所說,未來以及我們前進方向上,有許多非常正面的指標。

  • Relative to the second part of your question, the question of Alfa Wassermann, we are focusing -- that question is focused on a specific drug-development program. It has nothing to do with Xifaxan in total. It is a specific Xifaxan drug-development addition for a new indication. It does not impact our Xifaxan marketed product, I want to be very clear on that. And that's just a normal part of any discussion of a partnership, where you try to work together as a business. And the third part of your question, Gregg, I think go back to the Dermatology, and I think you're going to hear a lot from Bill about some of the positive steps he has taken to reinvigorate that growth, albeit we clearly said this year is a transition year for our Dermatology business, but let me turn it over to Bill.

    關於你問題的第二部分,也就是 Alfa Wassermann 的問題,我們目前聚焦——該問題是針對一個特定的藥物開發計畫。它與整體的 Xifaxan 無關。它是針對 Xifaxan 的一項特定藥物開發增補,用於新的適應症。它不會影響我們已上市的 Xifaxan 產品,我想把這點說得非常清楚。而這只是任何合作夥伴關係討論中的正常一部分,雙方會嘗試以商業方式一起合作。至於你問題的第三部分,Gregg,我想回到皮膚科(Dermatology),我想你會從 Bill 那裡聽到很多他為了重新激發成長所採取的正面措施;儘管我們也清楚表示今年是我們皮膚科業務的轉型年,但我把時間交給 Bill。

  • William D. Humphries - EVP and Company Group Chairman of Dermatology

    William D. Humphries - EVP and Company Group Chairman of Dermatology

  • Thanks, Joe. Gregg, we're stabilizing the business, selling 9 products through our sales force right now. We'll go to 10 products this month. So the ability to promote a full portfolio of dermatology and podiatry is an exciting base. In response to your question, I would stay we're stabilizing the base and volumes, and we're improving the base in terms of ASPs, which is consistent with our comments earlier on the call.

    謝謝,Joe。Gregg,我們正在讓業務趨於穩定,目前透過我們的銷售團隊銷售 9 項產品。這個月會增加到 10 項產品。因此,能夠推廣完整的皮膚科與足病科(podiatry)產品組合,是一個令人振奮的基礎。回應你的問題,我會說我們正在穩定基礎與銷量,同時在 ASP(平均銷售價格)方面改善基礎,這也與我們先前在電話會議中的評論一致。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Next question.

    下一個問題。

  • Operator

    Operator

  • Your next question comes from the line of Gary Nachman from BMO Capital Markets.

    您的下一個問題來自 BMO Capital Markets 的 Gary Nachman。

  • Gary Jay Nachman - Analyst

    Gary Jay Nachman - Analyst

  • For the B&L business, what are you doing to prepare for the new launches, Vyzulta and Luminesse? How big of an effort will you have? How big are these opportunities? And then, just walk through the benefit you're seeing in international, and if that's sustainable, seemed like it really helped you in the quarter.

    針對 B&L 業務,你們正在做哪些準備來迎接新產品上市——Vyzulta 和 Luminesse?你們會投入多大的力道?這些機會有多大?另外,也請說明一下你們在國際市場看到的助益,以及這是否可持續;看起來它在本季確實對你們幫助很大。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Well, thank you for your comment, Gary. You're absolutely correct. The B&L business is a really important part of our business. It represents over 50% of our business, and clearly, it's an area that we're very excited about for the future growth. On the question of our preparations, the team is working very hard on the Vyzulta product opportunity. I think as you may recall, we said at the last quarter, we've made some significant improvements in our Tampa facility to make sure that there was no questions in the Tampa facility. Number two, we've got a number of meetings. I was just out last week with some of the prescribers, key opinion leaders in the area of cataracts and surgery and some of the people that look at the area of glaucoma. So we're doing a lot of work with those key opinion leaders as we think about what the future messaging and opportunity with Vyzulta. I remind you that if you think about the entire treatment of glaucoma, approximately 2/3 of the market -- a little less than 2/3 of the market is for latanoprost or the Generics of Xalatan And so we're entering in with a great product, and we have the dual ability to have not only the [latanoprost but the bunod or] nitric oxide donation portion, which we think is going to make a big difference potentially for patients, so we're very excited about that.

    好的,謝謝你的評論,Gary。你說得完全正確。B&L 業務是我們業務中非常重要的一部分。它占我們業務的 50% 以上,而且很明顯,這是我們對未來成長非常興奮的一個領域。關於我們的準備工作,團隊正在非常努力推進 Vyzulta 的產品機會。我想你可能記得,我們在上一季提到,我們已在坦帕(Tampa)廠進行了一些重大改善,以確保坦帕廠不會有任何疑慮。第二,我們安排了多場會議。我上週才與一些處方醫師、在白內障與手術領域的關鍵意見領袖(KOL),以及一些關注青光眼領域的人士外出交流。因此,當我們思考 Vyzulta 未來的訊息傳遞與機會時,我們正與這些 KOL 做大量工作。我提醒你,如果你看整個青光眼治療市場,大約 2/3 的市場——略低於 2/3——是拉坦前列素(latanoprost)或 Xalatan 的學名藥。因此我們將以一個很棒的產品切入,而且我們具備雙重能力,不僅有 [latanoprost but the bunod or] 一氧化氮(nitric oxide)供體(donation)這一部分,我們認為這可能會為病患帶來很大的差異,所以我們對此非常興奮。

  • The Luminesse product, that's a product that is an over-the-counter product. We think it's an exciting opportunity for this ocular redness. Joe Gordon and his team are doing a lot of the work right now on some of the messages that need to be developed for it, but we think it's going to continue to build on what we think is a very successful platform for our over-the-counter Consumer business going forward.

    Luminesse 產品則是一個非處方(over-the-counter)產品。我們認為它在眼部發紅(ocular redness)方面是一個令人振奮的機會。Joe Gordon 和他的團隊目前正在針對需要建立的訊息做大量工作,但我們認為它將持續建立在我們的非處方消費者(Consumer)業務平台之上,而該平台我們認為未來會非常成功。

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • Yes, and Gary, it's Paul. I mean, just talking about the prospects on the international side, we're expecting to continue to see strength even relative to what we'd originally thought of through the balance of the year in the international group but particularly in what we call EMENA, which is Eastern Europe, Africa, Middle East. APAC, we're very strong in the APAC region and a little bit less in LatAm. And so as we look beyond Q1, as I think I reported out in my prepared remarks, we have a little bit of momentum there in the international side and we believe that will continue.

    是的,Gary,我是 Paul。談到國際市場方面的前景,我們預期國際事業群在今年剩餘期間將持續展現強勁表現,甚至會優於我們原先的預期,特別是在我們所稱的 EMENA,也就是東歐、非洲、中東。APAC 方面,我們在亞太地區(APAC)非常強勁,而在拉丁美洲(LatAm)則稍弱一些。因此,當我們展望第一季之後,正如我在事先準備的發言中所提到的,我們在國際業務端有一些動能,我們相信這將會延續。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Operator, next question.

    接線員,下一個問題。

  • Operator

    Operator

  • Your next question comes from the line of David Amsellem from Piper Jaffray.

    您的下一個問題來自 Piper Jaffray 的 David Amsellem。

  • David A. Amsellem - MD and Senior Research Analyst

    David A. Amsellem - MD and Senior Research Analyst

  • Just a question -- a longer-term question on the Dermatology business. So you talked about ASPs stabilizing, but as we head into the back half of the year and particularly next year and given the exposure to a lot of mature products, how should we think about ASPs, particularly as we get into next year? And then secondly, regarding SILIQ, can you talk about just the market dynamics there, in terms of how are you're going to attack promotion? Or how much -- what's the extent to which we're going to see significant DTC, it's a highly promotion-sensitive market, so maybe give us a little bit of detail on how you're planning to promote that product once you start getting in the field.

    只是個問題——一個關於皮膚科業務較長期的問題。你提到 ASP 正在趨於穩定,但當我們進入今年下半年、尤其是明年,且考量到你們曝險於許多成熟產品,我們應該如何看待 ASP,特別是進入明年之後?其次,關於 SILIQ,你能談談那裡的市場動態嗎?就你們打算如何推動促銷而言?或者說——我們會在多大程度上看到顯著的 DTC(直接面向消費者)推廣?這是一個對促銷高度敏感的市場,所以也請你提供一些細節,說明一旦你們開始進入市場端,打算如何推廣該產品。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Sure. Well, let me start and then Bill, if he thinks -- please, feel free to add to what I say. So I think it was a good question because, really, as we think about what's happening with our Dermatology business, the model changed, and it would change, and we're adjusting to that change. It's taken some time for us to work through that from a previous -- the previous management team's model, but we are changing. We are adapting to that change that's occurred in the marketplace. Relative though to the story of Dermatology, what I think you're going to hear is that as we thought about the opportunity with Walgreens, we thought it was a great opportunity. We've been working closely with Walgreens, and we think that they're great partners for the future. So I think we've made some changes to be flexible to work with the Walgreens program, and I think you're starting to see that. A year ago in the first quarter, second quarter, it was a challenging time of ASPs because, as you know, many of our products were going out the door at a relatively low ASP. We've now adjusted that. We've addressed the question. So we've made the progress for that. As it would relate to, though, the rest of the story, I think you referred to it as the long term, the story there for us is clearly going to be about new products. The first one is the opportunity to launch SILIQ or our brodalumab product, it's psoriasis then we've got the IDP-118. If approved, that's going to be another great opportunity for a long-term usage for potential topical usage in psoriasis depending on the label. Those are what we think are the exciting opportunities we see, and then there's a whole host of others behind that, I'm not going to go into a great detail now, but I think that's the real key. On the question of positioning on brodalumab and SILIQ, I think Bill may want to talk about it, but it's a big market. It's a $7-billion approximate market. If the market is growing ballpark 40%, so that's what we think is a really exciting opportunity. And if you talk to patients and Bill, a lot of it and talk to the key opinion leaders, the #1 problem patients have is the total clearance or 100% clearance of the plaques, and we think we have a product that based on the data is going to be very beneficial to patients, based on that clearance. I do think that it's not going to be something that's going to ramp up overnight, but as patients try it, because we have a receptor blocker, we have the, to our knowledge, the only receptor blocker approved, that's a big difference. As with any category of drugs pharmacologically, receptor blockers always tend to do better than an inhibitor of a pathway, just because the body can compensate for pathway inhibition, whereas you can't compensate for receptor blockers. That's the reason why we think we think it's a really exciting opportunity. I will be clear, we don't think it's going to ramp up overnight, but we think when patients try it, they'll realize the added efficacy for the future. Bill, anything you want to add?

    當然。我先開始回答,然後 Bill,如果你覺得——請隨時補充我所說的內容。我認為這是個好問題,因為實際上,當我們思考皮膚科業務正在發生什麼時,商業模式已經改變、也會改變,而我們正在調整以因應這個改變。我們花了一些時間,從先前——前一個管理團隊的模式中梳理並走出來,但我們正在改變。我們正在適應市場上已經發生的變化。就皮膚科的整體敘事而言,我認為你會聽到的是:當我們思考與 Walgreens 的合作機會時,我們認為那是個很好的機會。我們一直與 Walgreens 緊密合作,也認為他們是未來很棒的合作夥伴。因此我認為我們做了一些調整,以便更具彈性地配合 Walgreens 的方案,而你也開始看到這些變化。一年前在第一季、第二季,ASP 是一段具挑戰性的時期,因為如你所知,我們許多產品以相對較低的 ASP 出貨。我們現在已經調整了。我們已經回應了這個問題。因此在這方面我們已取得進展。至於其餘的敘事,我想你稱之為長期;對我們而言,長期的故事顯然會圍繞新產品。第一個是推出 SILIQ 或我們的 brodalumab 產品的機會,它用於乾癬;接著我們還有 IDP-118。若獲核准,依標籤而定,這將是另一個很好的機會,可望在乾癬上作為潛在外用、長期使用的產品。這些是我們認為令人興奮的機會;其後還有一整串其他項目,我現在不會深入細談,但我認為這才是關鍵。關於 brodalumab 與 SILIQ 的定位問題,我想 Bill 可能也想談談,但這是一個很大的市場。大約是 70 億美元的市場。若市場以約 40% 的幅度成長,這就是我們認為非常令人興奮的機會。而且如果你與病患交流——Bill 也一樣——並與關鍵意見領袖交流,病患的第一大問題是斑塊的完全清除或 100% 清除;我們認為依據數據,我們有一個產品能在這種清除效果上,對病患非常有益。我確實認為這不會是一夜之間就快速放量的事情,但當病患嘗試後,因為我們有受體阻斷劑;據我們所知,我們是唯一獲核准的受體阻斷劑,這是很大的差異。就任何藥物類別在藥理學上而言,受體阻斷劑通常總是比抑制某條途徑的藥物表現更好,因為身體可以對途徑抑制進行補償,但無法對受體阻斷進行補償。這就是我們認為——我們認為這是一個非常令人興奮的機會的原因。我會說清楚,我們不認為它會一夜之間放量,但我們認為當病患嘗試後,他們會意識到未來額外的療效優勢。Bill,你有什麼想補充的嗎?

  • William D. Humphries - EVP and Company Group Chairman of Dermatology

    William D. Humphries - EVP and Company Group Chairman of Dermatology

  • I would just add, on ASPs, we continue to look at beneficial product effects on patient assistance that support not only patients but physicians. And then on SILIQ, completely agree with Joe, right? It's a very active and exciting market. The focus is completely on patient outcomes, and there is a desire for that not only from patients but from physicians. On promotion we look at this as a very efficient audience, and -- so we're excited about having very intimate discussions with the prescribers that drive this category. And then finally on patient activation and our ability to compete, we're going to focus on working with the KOLs, certifying those physicians, pharmacies and patients to drive demand for this product.

    我只想補充,在 ASP 方面,我們持續關注有利的產品效益,以及對病患協助(patient assistance)的影響,這些不僅支持病患,也支持醫師。至於 SILIQ,我完全同意 Joe,對吧?這是一個非常活躍且令人興奮的市場。重點完全在病患結果(patient outcomes),而這種需求不僅來自病患,也來自醫師。在推廣方面,我們把這視為一個非常高效率的受眾——因此我們很期待能與推動此類別的處方醫師進行非常深入的討論。最後,在病患啟動(patient activation)以及我們的競爭能力方面,我們將專注於與 KOL 合作,認證那些醫師、藥局與病患,以帶動對該產品的需求。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Thank you. Operator, next question.

    謝謝。接線員,下一個問題。

  • Operator

    Operator

  • Your next question comes from the line of Umer Raffat from Evercore ISI.

    下一個問題來自 Evercore ISI 的 Umer Raffat。

  • Umer Raffat - Senior MD and Fundamental Research Analyst

    Umer Raffat - Senior MD and Fundamental Research Analyst

  • Joe, I guess, my question is -- what I'm trying to understand is given where your share price is currently, how should we be thinking about the equity especially as it relates to the price of stock at which the options were granted to most of your employees versus where the stock is. Do you need a big option repricing event? And how dilutive will that be? I guess, that's the real question.

    Joe,我想我的問題是——我試著理解的是,考量你們目前的股價,我們應該如何看待股權(equity),特別是就大多數員工獲授予期權時的股價,相對於目前股價而言。你們是否需要一次大規模的期權重新定價事件?那會造成多大的稀釋?我想,這才是真正的問題。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Sure. So obviously, we believe our share price is not where it should be. We believe it should be higher, to be clear. But fact is that's where it is today. I think what we're doing is working very hard every day, as Paul said, to reduce our debt. And we think if -- as we reduce our debt, we think that's going to help us tremendously with the share price going forward. On the questions of what we need to do from the -- with the team, we've been able to pull together a team that is absolutely committed to what we think is the turnaround opportunity of a lifetime. And so I think the team is committed to try to make these things happen because of some of the things that we are putting in place. I view the incentive programs, though, as a long-term issue. It's something that we put in place. We're focusing, as I think I've said in the previous call, the long-term incentive is going to be increasingly focused on return on capital. It's going to be -- have, for the performance share plan, it's also going to be focused on total shareholder return. So a lot of those things are really where I think you're going to see the real return through our team. But I think it's a long-term program. We'll continue to look at it, but I don't want to go so far as to say anything about options repricing or things like that. We'll continue to work with the board to think about all our alternatives, but I think we're looking at it as a long-term program, and we've got a team that's dedicated to try to turn this business around, because we do think it's the turnaround opportunity of a lifetime.

    當然。很明顯,我們認為我們的股價並不在它應該在的位置。講清楚,我們認為它應該更高。但事實是,今天它就在那個水準。我認為我們正在做的是每天非常努力地工作,如 Paul 所說,去降低我們的負債。我們認為,隨著我們降低負債,我們認為這將在未來對股價帶來極大的幫助。至於我們需要為團隊做些什麼,我們已經凝聚了一個團隊,他們對我們認為「一生一次的翻身機會」絕對投入。因此我認為,團隊願意致力於讓這些事情發生,因為我們正在建立的一些機制。不過,我把激勵計畫視為一個長期議題。這是我們已經建立的制度。我們的重點——如我在前一次電話會議中所說——長期激勵將會愈來愈聚焦於資本報酬(return on capital)。此外——就績效股票計畫(performance share plan)而言,也將聚焦於股東總報酬(total shareholder return)。因此,許多這類事情,我認為你將會看到真正的回報是透過我們的團隊來實現。但我認為這是一個長期計畫。我們會持續檢視,但我不想進一步談到期權重新定價或類似事項。我們會持續與董事會合作,思考所有替代方案,但我認為我們把它視為一個長期計畫;而我們有一個團隊致力於扭轉這門業務,因為我們確實認為這是一生一次的翻身機會。

  • Operator, next question.

    接線員,下一個問題。

  • Operator

    Operator

  • Your next question comes from the line of Christopher Schott from JPMorgan.

    下一個問題來自摩根大通(JPMorgan)的 Christopher Schott。

  • Christopher Z. Neyor - Analyst

    Christopher Z. Neyor - Analyst

  • This is Chris on for Chris. Can you elaborate on the progress you've made rightsizing your Dermatology portfolio? And how large is the field force today relative to your prior sizing? And just given the 2 [PDUFA] launches for SILIQ and IDP-118, how are you approaching the balance between restructuring and these upcoming launches?

    我是 Chris,代 Chris 提問。能否請您詳細說明在調整皮膚科產品組合規模(rightsizing)方面取得的進展?以及目前的業務代表團隊規模相較於先前的配置有多大?另外,考量 SILIQ 與 IDP-118 兩項 [PDUFA] 上市在即,您們如何在重組與這些即將到來的上市之間取得平衡?

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Sure. Well, I'll start -- it's Joe, and I'll give Bill a chance if he wants to add anything further, but relative to the activity in our Dermatology, we did a lot of work with Paul's arrival, my arrival and now Bill's arrival, just looking at were the resources we need to reach the key opinion leaders, to reach the prescribing dermatologists and podiatrist across the country. And we looked at it and said, previously we have 250 sales professionals, we think the right number for us, given our portfolio, given the opportunities in front of us and given the focus on the psoriasis, especially for some of these new products we said, was somewhere in the 150 sales professionals position. So we've now moved from 250 to 150 is the direct answer to that question. I think where we're going, though, is clearly to look at the opportunities for the psoriasis drugs and brodalumab and some of the things we'll focus on there. Bill, maybe you want to just talk a little bit about some of the activities of brodalumab and that potentially, if approved, the IDP-118.

    當然。我先開始——我是 Joe;如果 Bill 想補充,我也會讓他有機會。就我們皮膚科的相關活動而言,隨著 Paul 的加入、我的加入,以及現在 Bill 的加入,我們做了大量工作,檢視我們需要哪些資源,才能接觸關鍵意見領袖(KOL)、接觸全國各地的開立處方之皮膚科醫師與足病科醫師。我們檢視後認為,先前我們有 250 位銷售人員;以我們的產品組合、眼前的機會,以及對乾癬的聚焦(特別是一些新產品)來看,我們認為適合的規模大約是 150 位銷售人員。因此,我們已從 250 人調整到 150 人,這就是對該問題的直接回答。不過,我認為我們接下來的方向,顯然是要看乾癬用藥的機會、brodalumab,以及我們將聚焦的一些事項。Bill,也許你可以談談 brodalumab 的一些活動,以及若獲核准,IDP-118 的相關情況。

  • William D. Humphries - EVP and Company Group Chairman of Dermatology

    William D. Humphries - EVP and Company Group Chairman of Dermatology

  • Sure. So I look at us as having, again as I mentioned sort of efficient audience in the biologics space. So we have the opportunity to have a very targeted discussion with key prescribers to have discussions about SILIQ and the opportunity there. As you think about products in the pipeline and our opportunity to have engagement with not only with the top prescribers but also important healthcare providers that may work with physicians, we believe that our sales force of 150 is right now very efficient, and we'll be able, with the right amount of data and analysis and the excellent operations team we have here at Valeant, to really fine-tune our activity and make sure that our sales force is behaving in the most efficient way to support this product portfolio.

    好的。我看待我們的方式是——如我先前提到的——在生物製劑領域我們擁有相當有效率的受眾覆蓋。因此,我們有機會與關鍵處方醫師進行非常精準的溝通,討論 SILIQ 以及其機會。當你思考研發管線中的產品,以及我們不僅與頂尖處方醫師、也與可能與醫師合作的重要醫療照護提供者互動的機會時,我們相信目前 150 人的銷售團隊非常有效率;並且在 Valeant 這裡,憑藉適當的數據與分析,以及我們優秀的營運團隊,我們能真正微調我們的活動,確保銷售團隊以最有效率的方式運作,以支持這個產品組合。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Paul?

    Paul?

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • Yea, I -- it's Paul. I just want to pile on. I mean, I think this was part of the exercise for us looking at all of our business units and determining where we were underinvested in terms of annual OpEx and overinvested in OpEx intensity in the Derm space [patent], based on our analysis was that we're overinvested in OpEx in Derm and that with a sales force of circa 150 territories, we'd be in terrific position to be able to optimize the portfolio of assets we both have today but those assets that we expect to come out of the pipeline as well. The important element of that is that it enabled us to redeploy some of those resources to the areas where we felt we were underinvested, and that is the obvious one, it was the increase in the GI sales force in order to target the Primary Care segment but also to build up the -- as I called out in my prepared remarks, build out the patient access and sales ops teams that are necessary to be able to maximize the productivity of those very healthy investment that we make on an annual basis. So we think we're right sized.

    是的,我——我是 Paul。我只是想再補充一下。我的意思是,我認為這是我們檢視所有事業單位、並判斷在年度營運費用(OpEx)上哪些地方投資不足、以及在皮膚科領域的 OpEx 強度上哪些地方投資過度的一部分工作;根據我們的分析,我們在皮膚科的 OpEx 投資過度,而若銷售團隊約為 150 個轄區(territories),我們將處於極佳位置,能夠最佳化我們目前擁有的資產組合,以及我們預期也會從研發管線推出的資產。其中重要的一點是,這使我們能將部分資源重新部署到我們認為投資不足的領域;最明顯的是,擴增 GI(腸胃科)銷售團隊以鎖定基層醫療(Primary Care)客群,同時也強化——如我在事先準備的講稿中提到——病患可近性(patient access)與銷售營運(sales ops)團隊,這些都是必要的,才能最大化我們每年所做的、非常健康的投資之生產力。所以我們認為規模已調整到位(right sized)。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Thank you. Next question, operator.

    謝謝。接線員,下一個問題。

  • Operator

    Operator

  • Your next question comes from the line of David Risinger from Morgan Stanley.

    下一個問題來自摩根士丹利(Morgan Stanley)的 David Risinger。

  • Onusa Chantanapongwanij - Research Associate

    Onusa Chantanapongwanij - Research Associate

  • This is Onusa on the call for Dave. I have a 2-part question regarding the new guidance. So first regarding LOEs, should you please provide a framework for how the increase in guidance impacts the outlook for 2018? And second, regarding pending divestitures, what is the annual run rate of EBITDA yet to be excluded from guidance, because the deals are pending?

    我是 Onusa,代 Dave 提問。我有一個關於新指引的兩部分問題。第一,關於 LOE(專利到期/獨占期到期),能否請您提供一個架構,說明指引上調如何影響 2018 年的展望?第二,關於尚在進行中的資產剝離(divestitures),由於交易仍待完成,尚未自指引中排除的 EBITDA 年化運行率(annual run rate)是多少?

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • All right. Paul, you want to take this?

    好的。Paul,你要回答這題嗎?

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • Yes, I mean, you have a couple of things. I think, you'll find in that chart that we posted on the website you'll be able to see exactly what we think the impact is on 2017. I'd point out -- it's Slide 23 for those following along. I want to point out: one, we're not providing guidance for 2018; but second and very importantly, these assets we believe will go generic. And so whether they go later in 2017 or they even carry all forward into 2018, they are kind of a melting ice cube, and so you should treat that portfolio accordingly. I think, we've been I think quite transparent in helping you follow along by providing that Slide 23 that you can see the impact and to call it out. You'll see it's circa $110 million more revenue expected in 2017 than previously, and approximately the same amount of profitability due to the changed view of timing of these data uncertain LOEs. So regardless of when that occurs in '17, you got to think about the knock-on effect to '18. And when we provide '18 guidance, we'll let you know about that. The second question was...?

    是的,我的意思是,這裡有幾件事。我想你會在我們放在網站上的那張圖表中看到,我們認為對 2017 年的影響到底是什麼。我提醒一下——對於有在跟著看投影片的人,是第 23 頁。我想指出:第一,我們沒有提供 2018 年的指引;但第二、且非常重要的是,我們相信這些資產將會進入學名藥競爭(go generic)。因此,不論它們是在 2017 年較晚時點進入學名藥,或甚至全部延續到 2018 年,它們都像是一個正在融化的冰塊(melting ice cube),所以你應該以此方式看待該產品組合。我想我們一直相當透明,透過提供第 23 頁投影片,協助你跟進並看見影響、並把它點出來。你會看到,預期 2017 年營收比先前多約 1.10 億美元,而由於對這些時點不確定之 LOE 的時間判斷改變,獲利也大約增加相同幅度。所以不論它在 2017 年何時發生,你都必須思考對 2018 年的連鎖影響。等我們提供 2018 年指引時,我們會再告訴你相關情況。第二個問題是……?

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • The question of the pending divestments and where we are with the...

    關於尚在進行中的資產剝離,以及我們在……方面的進度。

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • Right. In -- with respect to guidance, and on that question, I said we reduced our guidance in -- and if you see the bridge to the change to the guidance, we reduced our guidance for adjusted EBITDA -- I'm sorry, we're -- for -- with respect to the divested skincare assets by a $70 million, and we reduced the -- our revenue expectations by $160 million. No other potential divestitures are currently considered in our guidance.

    對。就指引而言,針對那個問題,我說過我們在——如果你看指引變動的橋接表(bridge),我們針對調整後 EBITDA 的指引下修——抱歉,我們是——就已剝離的護膚資產(skincare assets)而言,我們將其影響反映為 7,000 萬美元;同時我們將營收預期下修 1.60 億美元。目前指引中未納入任何其他潛在的資產剝離。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • These -- I think Paul is -- I agree with everything Paul said, the only thing I'd say is that as we complete the sale of Dendreon, depending on the timing we'll build that in, but that's not in the numbers as we said right now.

    這些——我想 Paul 的說法我都同意;我唯一要補充的是,當我們完成 Dendreon 的出售時,視時間點而定我們會把它納入,但如我們目前所說,這尚未反映在數字中。

  • Operator, next question.

    接線員,下一個問題。

  • Operator

    Operator

  • Your next question comes from the line of David Maris from Wells Fargo Securities.

    下一個問題來自富國證券(Wells Fargo Securities)的 David Maris。

  • David William Maris - Senior Analyst

    David William Maris - Senior Analyst

  • A couple of quick things. First, Joe, on the Alfa Wassermann thing that Gregg mentioned, you mentioned that this is a drug development for a new indication. I thought this was for a new formulation, and it was the follow-on for Xifaxan. And also if they win in arbitration, they're looking for something like $300 million and the rights to that follow-on. I just want to get a confirmation of that. Then separately, Paul, a couple of housekeeping things. One, you mentioned that you reduced debt, but could you remind us what the leverage ratio was a year ago and what it is now? And then, also on the EBITDA calculation, you mentioned that in the beginning of the first quarter of '17, you no longer include adjustments for foreign exchange gains or losses. What did that contribute to the first quarter EBITDA and to the full year guidance?

    幾個快速問題。第一,Joe,關於 Gregg 提到的 Alfa Wassermann 那件事,你提到這是針對新適應症的藥物開發。我原本以為這是新劑型,且是 Xifaxan 的後續產品。另外,如果他們在仲裁中勝訴,他們尋求的似乎是約 3 億美元以及該後續產品的權利。我只是想確認一下是否如此。接著,Paul,幾個例行問題。第一,你提到你們降低了負債,但能否提醒我們一年前的槓桿比率(leverage ratio)是多少、現在是多少?另外,在 EBITDA 的計算上,你提到自 2017 年第一季初起,你們不再納入外匯損益的調整項。這對第一季 EBITDA 以及全年指引的貢獻是多少?

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • I'll start on the first part. David, on the Alfa Wassermann, the first comment I said is that, that is the result of a question or discussion between the 2 companies. We have made -- continue to make some progress with them, but we still have not resolved it yet. We look forward to getting it resolved in the near future. Specific to your question, though, it dealt with 2 issues, both a new formulation and a new indication. If I left out the indication, I'll respond to that as well. There -- it's 2 portions of the -- both a new indication and a new formulation are part of it. The important part for Valeant is that we have a number of different opportunities, including the Alfa Wassermann opportunity as well as other opportunities for formulations to take into the marketplace for a follow on Xifaxan. So I said before, our expectation is that this is -- has nothing to do with the Xifaxan current business today. This is simply for an opportunity to take it into a new formulation and into a new indication. Paul do you want to take the second part of the question from David relative to...

    我先從第一部分開始。David,關於Alfa Wassermann,我先前提到的第一點是,那是兩家公司之間某個問題或討論的結果。我們已經——並且仍在——與他們取得一些進展,但目前仍未解決。我們期待在不久的將來把它解決。不過就你的具體問題而言,它涉及兩個議題:一個是新的配方,另一個是新的適應症。如果我剛才漏掉了適應症,我也會一併回應。那——它分成兩個部分——新的適應症與新的配方都包含在其中。對Valeant而言,重要的是我們有多個不同的機會,包括Alfa Wassermann的機會,以及其他可帶入市場、作為Xifaxan後續產品的配方機會。所以我之前說過,我們的預期是,這——與目前Xifaxan今天的現有業務無關。這純粹是為了把它帶入新的配方以及新的適應症的一個機會。Paul,你要不要接著回答David問題的第二部分,關於……

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • Sure. Yes, sure, let's cover -- yes, the leverage first, and I'll go off of what you could calculate. The -- a year ago, our leverage would have been 6.3x. And if you calc the other way, you could calc using the publicly available information, you'd see that it was like 6.98x. And if you were able to adjust that for -- to pro forma for the divestiture of the skincare assets, it's approximately 6.75x. With respect to the question around FX, it's approximately $35 million in the quarter, relative to what it had been in the prior year quarter, had been a gain of about $2 million.

    當然。是的,當然,我們來談——是的,先談槓桿,我會以你可以自行計算的方式來說明。——一年前,我們的槓桿倍數會是6.3倍。如果你用另一種方式計算,利用公開可得資訊,你會看到大約是6.98倍。而如果你能就——以出售護膚資產作為備考(pro forma)調整,那大約是6.75倍。至於外匯(FX)的問題,本季約為3,500萬美元,相較於去年同期,去年同期約有200萬美元的收益。

  • David William Maris - Senior Analyst

    David William Maris - Senior Analyst

  • Okay. So of that $50 million increase for the year's guidance, something like $35 million in the quarter was contributed just from an accounting change of how you account for adjusted EBITDA with -- for FX?

    好的。所以在全年指引增加的5,000萬美元之中,本季大約有3,500萬美元只是來自於一項會計變更——也就是你們在調整後EBITDA中——對外匯的認列方式?

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • No.

    不是。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Operator, next question please.

    接線生,請下一題。

  • Operator

    Operator

  • Your next question comes from the line of Andrew Finkelstein from Susquehanna Financial group.

    下一個問題來自Susquehanna Financial Group的Andrew Finkelstein。

  • Andrew Jay Finkelstein - Research Analyst

    Andrew Jay Finkelstein - Research Analyst

  • I was hoping you could talk a bit more about how pricing and volume is playing out. You talked a bit about the ASPs in the Derm business. But since the third-party data aren't perfect, what are you seeing for the core segments in terms of price and volume? And how are formulary discussions shaping up for next year? Can we continue to see ASP improvement across your marketed products? And then, if there was any feedback you can share on the SILIQ pricing decision and how that plays into formulary coverage, that will be helpful.

    我希望你們能再多談一些定價與銷量的走勢。你們提到了一些皮膚科(Derm)業務的平均銷售價格(ASP)。但由於第三方數據並不完美,就核心事業部門而言,你們看到的價格與銷量表現如何?而明年的處方集(formulary)討論進展如何?我們是否能持續看到你們已上市產品的ASP改善?另外,如果你們能分享任何關於SILIQ定價決策的回饋,以及這如何影響處方集覆蓋,將會很有幫助。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Sure. So there's a lot involved in the question, if I miss any part of it, Paul, you can -- you add to it, but we've been working very hard in this question. And going back really for a year now, we've had a patient access and pricing committee set up in May of 2016 to really get to the heart of these questions and make sure that we're doing the right thing when it comes to pricing, gross-to-nets and all the activities there. On the general comment of your question, though, specific to where we are to -- this quarter versus a year ago, we have seen some brand price increase versus a year ago. There was a price positive to that in both in the Branded Rx and the Bausch + Lomb/International business is yes. Bausch + Lomb/International business on a constant currency basis also had a volume growth. As Paul said, it was -- but there was also some negative effects. So it was really those 3 combinations of -- for the Bausch + Lomb/International 1.41% or 1.5%, somewhere around there for the pricing, 1.5%, and some volume growth.

    好的。這個問題涵蓋很多內容,如果我漏掉任何部分,Paul,你可以——補充,但我們在這個議題上一直非常努力。而回顧其實從一年前開始,我們在2016年5月成立了病患可近性與定價委員會,真正要切入這些問題的核心,並確保在定價、毛額到淨額(gross-to-net)以及相關所有活動上,我們做的是正確的事。不過就你問題的一般性評論而言,具體到我們目前——本季相較一年前,我們確實看到部分品牌價格相較一年前有所上調。在品牌處方藥(Branded Rx)以及Bausch + Lomb/國際業務方面,這確實帶來了正向的價格影響。Bausch + Lomb/國際業務以固定匯率基礎來看也有銷量成長。如Paul所說,這——但也有一些負面影響。所以對Bausch + Lomb/國際而言,主要就是這三者的組合——定價約1.41%或1.5%,大概在那個區間,約1.5%,再加上一些銷量成長。

  • On the question, though, the gross-to-net as it was specifically talking about the entire company, and this is mostly -- this is really a U.S.-based comment predominantly. What we found is we've stabilized the gross-to-nets relative as a percentage of discount the total business versus a year ago, and so we're about stabilized with that, which I think was an important step in the right direction.

    不過就你提到的毛額到淨額(gross-to-net)問題而言,這是特別在談整家公司,而這主要——這其實主要是以美國為主的評論。我們發現,相較一年前,以折扣占整體業務的百分比來看,我們已經讓毛額到淨額趨於穩定,因此目前大致已穩定下來,我認為這是朝正確方向邁出的重要一步。

  • On the question of brodalumab, as we thought about where would we price branded SILIQ, we looked at all the factors, have a number of different conversations with our managed care [teams], our market access. We've looked at the conversation with the payers. We had conversation with the product profile forces, how we would position it. The discussions are going well, and that we think was partially because we made a decision to make it a competitively priced product and certainly on the affordable side of competitively priced. We think that's an important place to get trial. And once again, what I said before, once we get trial with this product, we do think that based on its efficacy, at least from what we've heard from many of the key opinion leaders and the critical investigators that have used the product, it is a very good, very efficacious product. Patients like this product, and that's where we're going to really be successful with it in the future. Thank you very much for the question. Operator, next question.

    至於brodalumab的問題,當我們思考要如何為品牌SILIQ定價時,我們考量了所有因素,並與我們的管理式醫療[團隊]、市場准入團隊進行了多次不同的對話。我們也與付款方(payers)進行了討論。我們也就產品特性與定位方式進行了討論。這些討論進展良好,我們認為部分原因是我們決定把它定為具競爭力的價格,而且在具競爭力的定價中屬於更可負擔的一端。我們認為這是促成試用(trial)的重要位置。再一次,如我之前所說,一旦這個產品獲得試用,我們確實認為,基於其療效——至少從我們從許多關鍵意見領袖以及使用過該產品的核心研究者那裡聽到的——它是一個非常好、非常有效的產品。病患喜歡這個產品,而這將是我們未來真正能在其上取得成功的地方。非常感謝你的提問。接線生,下一題。

  • Operator

    Operator

  • Your next question comes from the line of Annabel Samimy from Stifel.

    下一個問題來自Stifel的Annabel Samimy。

  • Annabel Eva Samimy - MD

    Annabel Eva Samimy - MD

  • You made some earlier comments about the reorganization efforts in B&L to improve efficiency and growth. So what do you think you still need to do improve efficiency and growth in that segment? It seems to be a franchise that's working for you. What are your expectations of where margins and growth can go? And over what time frame are we talking about?

    你先前提到在B&L進行重組以提升效率與成長的努力。那麼你認為在該事業部門,還需要做哪些事情來提升效率與成長?看起來這是一個對你們運作良好的特許經營(franchise)。你們對於利潤率與成長能提升到什麼程度有何預期?而我們談的是多長的時間範圍?

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • So that -- absolutely, you picked up exactly what I said. The point really for that was a couple of points. Number one, we've had some very good success with our Surgical business. We wanted to make sure that we brought the leadership for that Surgical business together. So that there was an oversight of looking at not just the existing business but also the new products, the opportunities -- the development opportunities as we work with the research and development team for new product opportunities like the Vitesse, like the Stellaris Elite. There was a good coordination going through the sales, the marketing and also, obviously, research and development. So we brought together that team. We now have an international head of the Surgical business as well as a U.S. head of the Surgical business. That -- those 2 dramatically make it much easier than to deal with 10, 15, 20 different countries. So that was Step 1. Step 2 was as we were going -- talking about the new launch like the Vyzulta. We brought together a team. We brought some additional people in, put in place there to support the new launch, and we were successful in recruiting a number of new sales reps into our Vyzulta team, and that's what we're preparing for right now. In addition, it's somewhat related to, although not exactly, we've done a lot, as Paul said, with our market access team to make sure that at least in U.S. we've got sufficient resources, so that the sales force will get the appropriate support for what we're trying to accomplish. And I think we're seeing some results. I mean, we've talked about what we saw in Asia. Asia is a great example, seeing great results in our contact lens business. We're seeing just good, strong market shares, et cetera. So that's what I think we've talked about with B + L/International. Those are really the 3 steps we took. So some steps in it to globalize some of the leadership; and number two, to bring on some additional sales force; and then some additional market access, other people to help us to be as successful with the business.

    所以——完全沒錯,你確實精準抓到我說的重點。這裡的重點其實有幾點。第一,我們的外科(Surgical)業務已經取得相當不錯的成果。我們希望確保把外科業務的領導團隊整合在一起。如此一來,就能在檢視不僅是既有業務、也包括新產品與機會——也就是在我們與研發團隊合作、尋找像 Vitesse、像 Stellaris Elite 這類新產品機會時的開發機會——方面,形成有效的監督與統籌。在銷售、行銷以及(當然)研發之間,也能有良好的協調。因此我們把那個團隊整合起來。我們現在同時設有外科業務的國際負責人,以及美國區外科業務負責人。這——這兩位的設置,讓事情變得容易得多,而不是要去對接 10、15、20 個不同國家。所以那是第 1 步。第 2 步是,當我們在推進——談到像 Vyzulta 這樣的新產品上市時。我們也把一個團隊整合起來。我們引進了一些額外人員並配置到位以支援新上市,同時也成功為我們的 Vyzulta 團隊招募了多位新的業務代表,而這正是我們目前正在準備的工作。另外,這在某種程度上相關、雖然不完全相同,正如 Paul 所說,我們在市場准入(market access)團隊方面做了很多工作,以確保至少在美國我們有足夠的資源,讓銷售團隊能獲得適當支援,以達成我們想要完成的目標。而我認為我們正在看到一些成果。我的意思是,我們談過我們在亞洲看到的情況。亞洲就是一個很好的例子,我們的隱形眼鏡業務表現非常出色。我們看到良好且強勁的市占率等等。所以我想,這就是我們談到的 B + L/International(博士倫/國際)部分。這些確實就是我們採取的 3 個步驟。也就是:第一,採取一些措施把部分領導架構全球化;第二,增補一些額外的銷售人力;第三,增加一些市場准入等其他人員,來協助我們讓這項業務更成功。

  • Annabel Eva Samimy - MD

    Annabel Eva Samimy - MD

  • And anything in terms of operating efficiency or margin in that business?

    那在該業務的營運效率或利潤率方面,有什麼可以分享的嗎?

  • Paul S. Herendeen - CFO and EVP of Finance

    Paul S. Herendeen - CFO and EVP of Finance

  • Well, there -- it's Paul speaking. Yes, there is definitely some opportunity for margin improvement. I even called out and said, yes, you look to see some operating -- they never use 1 quarter to project forward many years, but we're able to get some operating expense efficiency in the B&L International segment, simply by virtue of taking a look at each individual unit, as Joe said, organizing it under 1 leader, Tom Appio, who now runs that business globally. There are opportunities to combine, to be more efficient, to deploy resources, where we have our greatest growth opportunities. So yes, we have the opportunity to potentially increase the operating margins across that business.

    嗯——這裡是 Paul 發言。是的,利潤率改善確實有一些機會。我甚至也特別提到並說過,是的,你會去看是否能在營運——他們從不會用單一季度去推估未來很多年,但我們確實能在 B&L International(博士倫國際)部門取得一些營業費用效率,原因很簡單:如 Joe 所說,我們逐一檢視每個單位,並把它們整合在一位領導者之下,也就是現在在全球負責該業務的 Tom Appio。我們有機會進行整併、提升效率,並把資源部署到我們成長機會最大的地方。所以是的,我們有機會在整個業務範圍內潛在地提升營業利潤率。

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Operator, we have time for 1 more question, please.

    接線員,我們還有時間再問 1 個問題,謝謝。

  • Operator

    Operator

  • Your last question comes from the line of Tim Chiang from BTIG.

    最後一個問題來自 BTIG 的 Tim Chiang。

  • Timothy Chiang - Analyst

    Timothy Chiang - Analyst

  • Could you guys talk a little bit more about GI franchise you guys have? I know you guys have shored up some of your sales and marketing aspect. I looked at Relistor, for instance, you guys highlighted that the prescription trends were up, but I noticed that the net sales were down. And could you just comment on some of the other GI products that you have? How you sort of plan on growing them throughout this year?

    你們能否再多談一點你們的 GI(腸胃)產品線(franchise)?我知道你們已經強化了一些銷售與行銷面向。以 Relistor 為例,你們強調處方趨勢上升,但我注意到淨銷售額卻下降。也請你們評論一下你們其他的 GI 產品。你們今年打算如何推動它們的成長?

  • Joseph C. Papa - Chairman of the Board and CEO

    Joseph C. Papa - Chairman of the Board and CEO

  • Sure. So first and foremost, on the GI franchise, we said versus as a year ago, there was some challenges early in the first quarter. Those challenges that we dealt with, dealt with some of the noise that occurred as a result of the rumors about us selling the Salix business. We think we've corrected those questions, number one. Number two, we added a Primary Care capability. We believe that Primary Care capability was absolutely critical for us and in terms of its -- our ability to reach the Primary Care physician, where much of the IBS-D is prescribed as well as clearly where a lot of the Relistor usage is. So with that additional capability, we're seeing some positive trends, the Primary Care, new Rx share gains for the trailing 8 weeks from before. And now that we have it, we gained 440 basis points from before the Primary Care till the 8 weeks after it. When you look at Xifaxan new Rxs, we saw a 10% gain from January through March. Apriso was up 9%. Relistor was up 12% year-over-year. So we are seeing the gains, we think mostly because of we've added incremental sales force. And it goes back to what I think Paul mentioned in his comments, it's really about us taking a look at where do we want to make the investments in our -- utilization of our resources, whether it be the sales force capability, the advertise and promotion capability, but those allocations were what we needed to do and we did it, and we now are starting to see some of the results.

    當然。首先,就 GI 產品線而言,我們說過,相較於一年前,第一季初期確實有一些挑戰。我們所面對的那些挑戰,部分來自於市場雜音——也就是因為外界傳聞我們要出售 Salix 業務而產生的影響。我們認為我們已經把那些疑慮釐清了,這是第一點。第二點,我們新增了基層醫療(Primary Care)的能力。我們相信這項基層醫療能力對我們至關重要,因為它關係到——我們觸及基層醫師的能力;而許多 IBS-D 的處方是在基層醫療端開立,當然 Relistor 的大量使用也同樣在那裡發生。因此,隨著這項新增能力,我們看到一些正向趨勢:在過去 8 週的滾動期間(trailing 8 weeks),基層醫療端的新處方(new Rx)市占率相較之前有所提升。而在導入基層醫療能力後,我們在導入前到導入後 8 週之間提升了 440 個基點。再看 Xifaxan 的新處方,我們在 1 月到 3 月期間看到 10% 的成長。Apriso 成長 9%。Relistor 年增 12%。所以我們確實看到成長,我們認為主要原因是我們增加了額外的銷售人力。而這也回到我想 Paul 在評論中提到的:關鍵在於我們檢視我們要把投資放在哪裡——我們資源的運用,不論是銷售團隊能力、廣告與推廣(advertise and promotion)能力;而這些資源配置正是我們需要做的,我們也做了,現在開始看到一些成果。

  • Operator, that's going to conclude my comments. I thank everyone for joining us today and very much look forward to answering additional question anyone has as we go forward. Thank you everyone. Have a great day. Thanks for joining us.

    接線員,以上將結束我的發言。感謝各位今天加入我們,也非常期待在未來繼續回答大家的其他問題。謝謝各位。祝大家今天愉快。感謝參與。

  • Operator

    Operator

  • And ladies and gentlemen, this concludes today's conference call. You may now disconnect.

    各位女士、先生,今天的電話會議到此結束。您現在可以掛線。